DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21437/S-013

SUPPLEMENT APPROVAL

G.D. Searle LLC
c/o Pfizer, Inc.
Attention: Marcio de Godoy, MBA, PharmD, PhD
Senior Manager, Worldwide Safety and Regulatory
500 Arcola Road, G4347
Collegeville, PA 19426

Dear Dr. de Godoy:

Please refer to your Supplemental New Drug Application (sNDA) dated 3 November 2015, received 3 November 2015, and your amendment received 19 January 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Inspra (eplerenone) 25 mg and 50 mg tablets.

This Prior Approval supplemental new drug application provides for the following revisions to the Full Package Insert:

- Numerous editorial and organizational revisions to improve clarity and succinctness.
- DOSAGE AND ADMINISTRATION - Dosing instructions and monitoring for use with concomitant CYP3A inhibitors were revised.
- Use of 'CYP3A4' versus 'CYP3A' was clarified throughout the label where applicable to describe the interaction and advice for use with INSPRA.
- WARNINGS AND PRECAUTIONS - Language regarding use in patients with impaired hepatic function was removed because it is more appropriately described in Section 12 Clinical Pharmacology.
- ADVERSE REACTIONS - This section was revised to remove adverse reactions that were not considered plausibly related to INSPRA.
- DRUG INTERACTION - Language regarding use with CYP3A4 inhibitors was revised.
- USE IN SPECIFIC POPULATIONS - Section 8.4 Pediatric Use was updated to correct the age ranges for the pediatric populations studied. Section 8.5 Geriatric Use was updated to describe the potential increased risk of hyperkalemia in this population.
- CLINICAL PHARMACOLOGY - Section 12.3 Pharmacokinetics absorption and distribution language was clarified. Language describing the interaction of INSPRA with CYP3A inhibitors was revised.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Bridget Kane, Regulatory Project Manager, at (240) 402-2170.

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, MD, PhD
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NORMAN L STOCKBRIDGE
05/04/2016